Thermo Fisher (TMO) Scientific announced it has received approval from the U.S. Food and Drug Administration for its Oncomine Dx Target Test as a companion diagnostic. The test is approved to identify patients with non-small cell lung cancer whose tumors have HER2 activating mutations, making them eligible for treatment with Boehringer Ingelheim’s HERNEXEOS.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Trinity Biotech announces launch of FDA-cleared preeclampsia testing service
- Thermo Fisher’s Strong Market Position and Growth Drive Buy Rating
- Thermo Fisher’s Strong Performance and Strategic Initiatives Justify Buy Rating Amid Industry Recovery
- Positive Outlook and Strategic Growth Plans Bolster Thermo Fisher’s Stock Rating
- Thermo Fisher price target raised to $490 from $450 at Barclays